Melanotan I vs GHK-Cu
Side-by-side comparison of Melanotan I and GHK-Cu: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
Melanotan I
GHK-Cu
Melanotan I
Melanotan I (afamelanotide) is a linear synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) with the substitution of norleucine at position 4 and D-phenylalanine at position 7. Unlike Melanotan II (which is…
Lowest listed price: $35.00 across 4 listings
Full Melanotan I profileGHK-Cu
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a molecule Pickart and Thaler first pulled out of human plasma in 1973. The free peptide (GHK, C14H24N6O4) weighs about 340.4 Da; bind it 1:1…
Lowest listed price: $34.99 across 7 listings
Full GHK-Cu profileSide-by-side comparison
| Attribute | Melanotan I | GHK-Cu |
|---|---|---|
| Category | Other | Skin, Hair & Aesthetics |
| Research Stage | FDA Approved | Approved/marketed as a topical cosmetic ingredient (Copper tripeptide-1) with supporting small human studies. Injectable use is preclinical/off-label, research-use-only, with no human clinical trials. |
| Mechanism of Action | Melanotan I is afamelanotide, i.e. [Nle4, D-Phe7]-alpha-MSH ('NDP-alpha-MSH'), a synthetic 13-amino-acid analog of alpha-melanocyte-stimulating hormone. The Nle4 and D-Phe7 substitutions make it resistant to enzymatic breakdown and roughly 10-100x more potent… | GHK-Cu works mostly as a copper shuttle and a signaling peptide. It binds Cu(II) with high affinity (log K around 16.4, close to albumin's 16.2) and can supply or regulate copper for copper-dependent enzymes like SOD1, lysyl oxidase, cytochrome c oxidase, and… |
| Half-Life | Controlled-release subcutaneous implant (Scenesse): high inter-subject variability; median Tmax ~36 h, mean Cmax ~3.7 ng/mL, apparent terminal half-life ~15 h, with plasma levels measurable to ~96 h post-dose (FDA pharmacokinetics, n=12). Injected/bolus free peptide: peak plasma at ~1-2 h with an elimination half-life of ~30 minutes; the Nle4/D-Phe7 modifications prolong biological (melanogenic) activity well beyond plasma clearance. | ~30-60 min (plasma; approximate legacy figure, no robust modern human PK study) |
| Typical Dose Range | 16 mg | 200-500 mcg SC daily (community/RUO; no clinically established injectable dose) |
| Dosing Frequency | every_1_to_4_weeks | Once daily subcutaneous; some run 5 days on / 2 days off. Topical: 1-2x daily to cleansed skin. |
| Administration | Subcutaneous, Intramuscular | Subcutaneous, Topical |
| Side Effects | Generally mild. Commonly reported: transient nausea (usually milder and less frequent than with Melanotan II), facial flushing, headache, fatigue, and skin hyperpigmentation including darkening of existing moles, freckles and nevi. Implant-site reactions occur… | Topical GHK-Cu is generally well tolerated; higher-concentration formulations (4-5%) raise the odds of irritation, redness, or stinging. Injectable use has no safety data from controlled trials; the main theoretical concern is copper accumulation with repeated… |
| Molecular Weight | 1646.85 g/mol (average; molecular formula C78H111N21O19) | Free peptide (GHK): 340.38 Da (C14H24N6O4). Copper complex (GHK-Cu): 401.9 Da (C14H22CuN6O4, neutral 1:1 Cu(II) complex). |
| Common Vial Sizes | 5, 10 | 50 mg, 100 mg |
Price History
2 data points- Ion Peptide
- Disguised Alpha
Price History
4 data points- OF
- BM
- Half Nattys
- BHG Labs
Melanotan I: potential benefits
- Increased melanin (eumelanin) production and skin darkening via MC1R activation, with a reduced UV requirement
- FDA-approved photoprotection in erythropoietic protoporphyria (EPP) as the Scenesse 16 mg subcutaneous implant [PMID:26132941]
- Reduced phototoxic pain and improved quality of life in EPP patients in randomized controlled trials [PMID:26132941]
- Tends to produce fewer MC4R-type effects (spontaneous erections, strong libido, marked nausea) than the cyclic Melanotan II - attributable to Melanotan II's greater potency and metabolic stability, not to true MC1R selectivity of Melanotan I
- Investigated in research settings for photoprotection in UV-sensitive populations
GHK-Cu: potential benefits
- Stimulates type I collagen synthesis in human fibroblasts at low nanomolar-to-picomolar concentrations (PMID: 3169264)
- Increases glycosaminoglycans (dermatan/chondroitin sulfate) and upregulates decorin in wound models (PMID: 11121126)
- Modulates matrix metalloproteinases and their inhibitors, partially correcting the MMP-9/TIMP-1 imbalance in a smoke-induced emphysema model (PMID: 35936787)
- Drives tissue remodeling and chemoattracts macrophages, mast cells, and capillary cells to injury sites (PMID: 18644225)
- Modulates expression of ~4,000+ human genes via the Broad Institute Connectivity Map, including DNA-repair and antioxidant genes (PMID: 25302294)
- Increases stemness and proliferative potential of epidermal basal cells and keratinocytes (PMID: 23019153)
- Acts as an antioxidant and anti-inflammatory copper regulator in the context of aging (PMID: 22666519)
- Broad skin-regeneration effects on collagen, proteoglycans, MMPs, and immune/endothelial cell recruitment (PMID: 26236730)
Frequently asked
What's the difference between Melanotan I and GHK-Cu?
Melanotan I is a other that melanotan i is afamelanotide, i.e. [nle4, d-phe7]-alpha-msh ('ndp-alpha-msh'), a synthetic 13-amino-acid analog of alpha-melanocyte-stimulating hormone. the nle4 and d-phe7…. GHK-Cu is a skin, hair & aesthetics that ghk-cu works mostly as a copper shuttle and a signaling peptide. it binds cu(ii) with high affinity (log k around 16.4, close to albumin's 16.2) and can supply or regulate copper…. The two differ in mechanism, half-life (Controlled-release subcutaneous implant (Scenesse): high inter-subject variability; median Tmax ~36 h, mean Cmax ~3.7 ng/mL, apparent terminal half-life ~15 h, with plasma levels measurable to ~96 h post-dose (FDA pharmacokinetics, n=12). Injected/bolus free peptide: peak plasma at ~1-2 h with an elimination half-life of ~30 minutes; the Nle4/D-Phe7 modifications prolong biological (melanogenic) activity well beyond plasma clearance. vs ~30-60 min (plasma; approximate legacy figure, no robust modern human PK study)), and typical dose range.
Which has the longer half-life, Melanotan I or GHK-Cu?
Melanotan I has a half-life of Controlled-release subcutaneous implant (Scenesse): high inter-subject variability; median Tmax ~36 h, mean Cmax ~3.7 ng/mL, apparent terminal half-life ~15 h, with plasma levels measurable to ~96 h post-dose (FDA pharmacokinetics, n=12). Injected/bolus free peptide: peak plasma at ~1-2 h with an elimination half-life of ~30 minutes; the Nle4/D-Phe7 modifications prolong biological (melanogenic) activity well beyond plasma clearance.. GHK-Cu has a half-life of ~30-60 min (plasma; approximate legacy figure, no robust modern human PK study). Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, Melanotan I or GHK-Cu?
Lowest listed price on BodyHackGuide: Melanotan I from $35.00, GHK-Cu from $34.99. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack Melanotan I and GHK-Cu?
Stacking depends on mechanism overlap, safety profile, and goals. Melanotan I and GHK-Cu should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy Melanotan I or GHK-Cu
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.